FIGURE 1



MV411 (CD33+), AML
Tumor volume (mm3)
1400
1200
1000
800
600
400
200
0
3
6
9
12
15
18
21
24
27
30
33
36
39
42
45
Days
Vehicle
CD33AB – Compound (Ia) DAR3.07, 3mg/kg x 1
CD33AB – Compound (Ie) DAR3.25, 2.83mg/kg x 1
CD33AB – Compound (Ih) DAR3.08, 2.99mg/kg x 1
Mylotarg, 0.1mg/kg x 1
Venetoclax 50mg/kg x 21
CC90009 5mg/kg bid x 10

FIGURE 2

	Cell proliferation assay IC50 (M)		AB1-Compound I(a) Conjugate data		
	Cell Line	Description	CC-885 IC50 (M	AB1-Compound I(a) Conjugate data	Mylotarg (M)
1	MV-4-11	leukemia, biphenotypic B myelomonocytic	3.02E-10	2.64E-11	5.32E-11
2	ML-2	leukemia, acute myelomonocytic leukemia	2.82E-10	2.63E-11	5.02E-11
3	HL-60	leukemia, acute promyelocytic	2.43E-10	2.41E-11	3.26E-10
4	SKNO-1	leukemia, acute myeloid leukemia	1.51E-10	2.89E-11	1.34E-08
5	F-36P	leukemia, myelodysplastic syndrome	2.86E-10	7.24E-09	>2.00E-8
6	Kasumi-6	leukemia, acute myeloid, myeloblast	3.84E-10	9.64E-11	>2.00E-8
7	OCI-AML-4	leukemia, acute myeloid leukemia	4.14E-10	5.45E-11	2.37E-10
8	MoIm-13*	leukemia, acute, myeloid,leukemia suspense leukemia	1.51E-09	1.40E-10	2.70E-11
9	AML-193	leukemia, acute monocytic, monocyte	4.01E-10	1.23E-10	>2.00E-8
10	EoL-1*	leukemia, Human eosinophilic leukaemia	3.48E-10	5.18E-11	6.87E-11
11	HNT-34*	leukemia, acute myeloid leukemia	1.12E-10	5.36E-11	3.77E-09
12	Kasumi-3	leukemia, actue myeloblastic leukemia	1.40E-10	>2.00E-8	>2.00E-8

	Cell proliferation assay IC50 (M)		AB1-Compound I(a) Conjugate data		
	Cell Line	Description	CC-885	AB1-Compound I(a) Conjugate data	Mylotarg
1	OCI-AML-1	leukemia, acute myeloid leukemia	4.24E-10	1.50E-08	2.24E-10
2	OCI-AML-2	leukemia, acute myeloid leukemia	1.76E-09	5.65E-09	3.94E-11
3	OCI-AML-3	leukemia, acute myeloid leukemia	1.87E-09	>2.00E-8	4.26E-09
4	OCI-AML-5*	leukemia, acute myeloid leukemia	1.16E-09	1.50E-10	7.83E-11
5	OCI-AML-6*	leukemia, acute myeloid leukemia	3.13E-10	7.12E-09	>2.00E-8
6	KG-1	leukemia, acute myelogenous	8.47E-10	>2.00E-8	>2.00E-8
7	KO52	leukemia, acute myeloblastic leukemia	5.93E-10	>2.00E-8	>2.00E-8
8	KG-1a	leukemia, acute myeloid leukemia	8.47E-10	>2.00E-8	>2.00E-8
9	NOMO-1	leukemia, acute monocytic leukemia	6.15E-10	>2.00E-8	>2.00E-8
10	KASUMI-1	leukemia, acute myeloblastic	9.16E-10	>2.00E-8	>2.00E-8
11	OCI-M1	leukemia, acute myeloid leukemia	4.70E-09	>2.00E-8	>2.00E-8
12	PLB-985	leukemia, acute myeloid leukemia (derivative	4.46E-10	1.11E-10	7.14E-08
13	MKPL1	leukemia, acute myeloblastic leukemia	8.46E-10	>2.00E-8	>2.00E-8

FIGURE 3




MV4-11
Tumor volume (mm3)
1200
1000
800
600
400
200
0
1
4
7
10
13
16
Days
Vehicle
AB1 Compound I(a) Conjugate DAR4.1, 3 mg/kg x 1
AB1 Compound I(i) Conjugate DAR3.38, 3.64 mg/kg x 1
AB1 Compound I(d) Conjugate DAR3.39, 3.74 mg/kg x 1
AB1 Compound I(j) Conjugate DAR2.96, 4.16 mg/kg x 1
AB1 Compound I(e) Conjugate DAR3.04, 4.05 mg/kg x 1
AB1 Compound I(k) Conjugate DAR3.19, 3.86 mg/kg x 1
Mylotarg, 0.1 mg/kg x 1
Gemtuzumab Compound I(a) Conjugate DAR4.4, 3 mg/kg x 1
CC-90009, bid x 10

FIGURE 4



Conjugate	CD33AB-Cmpd I(a)	Gemtuzumab-Cmpd I(a)
%D0	6	22
%D2	33	24
%D4	37	36
%D5	8	--
%D6	15	14
%D8	2	4
Average DAR	3.6	3.4





FIGURE 5


MV4-11
Tumor volume (mm³)
Days
Endpoint
Vehicle
Gemtuzumab Compound I(a) Conjugate DAR3.25, 3mg/kg x 1
Gemtuzumab Compound I(a) Conjugate DAR3.25, 5mg/kg x 1
CD33AB Compound I(a) Conjugate DAR3.07, 3mg/kg x 1
CD33AB Compound I(a) Conjugate DAR3.07, 5mg/kg x 1
Gemtuzumab IgG1 LALA Compound I(a) Conjugate DAR3.15, 3mg/kg x 1
Gemtuzumab IgG1 LALA Compound I(a) Conjugate DAR3.15, 5mg/kg x 1
Gemtuzumab Compound I(e) Conjugate DAR2.59, 5mg/kg x 1
Venetoclax 25mg/kg x 21
Venetoclax 50mg/kg x 21




FIGURE 6B

FIGURE 6A